See the moon, Venus and the Pleiades make a celestial triangle in the predawn sky on June 22

When you buy through links on our articles, Future and its syndication partners may earn a commission.
Look to the east before sunrise on June 22 to catch the delicate form of the crescent moon shining with Venus alongside the Pleiades star cluster.
Stargazers in the U.S. can find the cosmic trio loitering above the eastern horizon in the hours preceding dawn on Sunday, June 22. Venus will be visible shining to the lower right of the sickle-like shape of the waning crescent moon, while the Pleiades open star cluster can be found less than 10 degrees (one fist's width at arm's length) to the lower left of the lunar disk.
The Pleiades will be the last of the three bodies to rise above the horizon at around 3.15 a.m. ET (0715 GMT) on June 22, and will be visible for a little over an hour before it becomes challenging to spot in the glare of the rising sun. As always the utmost care must be taken to never point telescopic equipment or binoculars close to the rising sun, as doing so can immediately and permanently damage your vision.
TOP TELESCOPE PICK:
Want to see the moon, Venus or the Pleiades up close? The Celestron NexStar 4SE is ideal for beginners wanting quality, reliable and quick views of celestial objects. For a more in-depth look at our Celestron NexStar 4SE review.
The strange cosmic triangle is a perfect example of the astounding variety of objects that are visible to the naked eye from Earth. The moon, for example, is a relatively small, barren world scarred by craters and dark lunar seas born of brutal asteroid bombardments that occurred billions of years ago. As the moon progresses through the different phases of the lunar calendar, the sun's light throws new impact sites, barren plains, and swathes of broken landscapes into relief as prime targets for amateur astronomers wielding binoculars and backyard telescopes.
Venus, meanwhile, is a rocky world that shares a similar size, mass and density with our planet, which has led to it being nicknamed 'Earth's twin'. However, telescopic and robotic observations are steadily unravelling the mystery of how the planet followed a radically different evolutionary path that saw a runaway greenhouse gas effect render it hostile to life as we know it. It is possible to observe the different phases of the Venutian disk - which are similar to the phases of the moon - using a telescope with a 60 mm aperture (or greater) with a minimum of 50x magnification, per telescope-maker Celestron.
The Pleiades star cluster (also known as Messier 45) is a different beast entirely — a gravitationally bound collection of over a thousand stars found within the Milky Way some 445 light-years from Earth in the Taurus constellation, according to NASA. The Pleiades are readily visible as a smudge of light to the naked eye under dark sky conditions, but a pair of 10x50 binoculars will help you witness their true nature, and distinguish individual stars. The view will become even more spectacular with the aid of a 6-inch telescope, revealing more of the dazzling blue-white stars.
Stargazers hoping to explore the wonders of the universe for themselves should check out our guide to the best telescopes and binoculars on offer in 2025. Photographers hoping to capture the next big astronomy event should also check out our roundup of the best cameras and lenses for astrophotography.
Editor's Note: If you capture an image of the moon with Venus and the Pleiades and want to share it with Space.com's readers, then please send your photo(s), comments, and your name and location to spacephotos@space.com.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

CBS News

an hour ago

• CBS News

Thousands of kids take part in T.D. Jakes Foundation STEAM Expo

Thousands of children and families gathered Saturday at the Shops at RedBird for the T.D. Jakes Foundation's second annual STEAM Expo, a hands-on event designed to spark curiosity and creativity in science, technology, engineering, arts and math. Hands-on learning inspires young minds Excited lines of kids and parents streamed into the venue, where they explored interactive booths, live demonstrations and family-friendly activities. Topics ranged from human anatomy and artificial intelligence to sports medicine and forestry. Five-year-old Leondri Stiggle was especially enthusiastic about the science experiments. "It feels hot, so hot! We made lotion, and it feels like it's juice," she said. Her father, Leon Stiggle, said he wished he had access to similar opportunities as a child. "When you start early, it always evolves into something better," he said. "It's good they have this program — shout out to T.D. Jakes. Appreciate it!" Juneteenth education adds cultural depth The event also featured educational exhibits on Juneteenth, including live actors portraying historical figures such as Fort Worth's Dr. Opal Lee, known as the "grandmother of Juneteenth." The Southwest Dallas County Alumnae Chapter of Delta Sigma Theta Sorority Inc. sponsored the exhibit. "We also have other living exhibits where you can learn about the Emancipation Proclamation and educational development," said chapter president Maiya Bangurah. Building a future-ready workforce Kelley Cornish, president of the T.D. Jakes Foundation, said the expo marked the nonprofit's 10th pop-up event in two years. "People don't realize what an incredible field this is," Cornish said. "We've learned that 2.4 million jobs go unfilled every year because there's no pipeline. We're starting early. Exposure to these careers can literally change a family's dynamic." The foundation's next event is scheduled for the fall.

Yahoo

4 hours ago

• Yahoo

Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform' Rating

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 10 biotech stocks screaming a buy. On June 17, Wolfe Research initiated coverage of the stock with an 'Outperform' rating and a $49 price target. The research firm reiterated the company's solid position amid the 'TTR craze' while also echoing its commercial execution strategy. A medical technician wearing a lab coat operating machinery in a biopharmaceutical laboratory. Consequently, Wolfe Research expects BridegBio's revenue to total $569 million in 2025 before rising to $3.4 billion by 2028. It should peak at $4.4 billion in 2034. For the upcoming second quarter, the research firm expects the company to deliver revenue of $106 million, slightly below market expectation of $111 million. While the stock has shown a remarkable return of 42% year to date, Wolfe Research insists it must navigate several challenges to maintain the positive momentum. It must navigate the potential Vyndaqel loss of exclusivity, achondroplasia data versus competition, and pipeline products. In addition, consistent revenue growth and expanding operating margins will be crucial to the company's long-term success. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biopharmaceutical company that develops and delivers transformative medicines for genetic diseases. Its pipeline includes a range of development programs, from early science to advanced clinical trials. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Sign in to access your portfolio

Yahoo

4 hours ago

• Yahoo

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice president and chief development officer, effective January 2026. Holly Kordasiewicz, Ph.D., currently senior vice president of neurology, will take over the role. Geary has been with Ionis since 1995 and played a pivotal role in bringing six medicines to regulatory approval, including the company's first independently commercialized drug, TRYNGOLZA. A biotechnologist pouring liquid into a test tube and analyzing its components in a lab. Dr. Kordasiewicz, who joined Ionis in 2011, brings over 20 years of experience in R&D, particularly in neurology. She leads the company's neurology program, covering treatments for conditions such as Alzheimer's disease, Angelman syndrome, and Alexander disease. Her work has also contributed to key partnered programs with Biogen, including the development of QALSODY® and IONIS-MAPTRx. As Dr. Geary transitions out of his role, he will continue as a strategic consultant through 2026 to ensure continuity. Ionis leadership praised both Geary's legacy and Kordasiewicz's appointment as a pivotal step in driving the company's commitment to developing transformational therapies for patients with serious diseases. Ionis Pharmaceuticals, Inc. is a U.S.-based commercial-stage biotech company specializing in RNA-targeted therapies. Its approved products include TRYNGOLZA for FCS, WAINUA, and TEGSEDI for ATTRv-PN, SPINRAZA for spinal muscular atrophy, QALSODY for ALS, and WAYLIVRA for rare lipid disorders. The company has a robust pipeline, including late-stage programs like Olezarsen (for hypertriglyceridemia), Donidalorsen (for hereditary angioedema), and Zilganerse (for Alexander disease), along with several mid-stage treatments for neurological and metabolic conditions. Ionis also collaborates with leading pharma firms, including Biogen, GSK, AstraZeneca, Novartis, Roche, and Metagenomi, expanding its reach in developing transformative RNA therapies. While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None.